We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| HLS Therapeutics Inc | TSX:HLS | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.24 | 6.38% | 4.00 | 3.70 | 4.00 | 4.00 | 3.76 | 3.76 | 5,548 | 21:10:15 |
From May 2023 to May 2024
TORONTO, Oct. 26, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2023 financial results on Thursday, November 9, 2023. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. Tim Hendrickson, Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
CONFERENCE ID: 52567994
DATE: Thursday, November 9, 2023
TIME: 8:30 a.m. ET
WEBCAST LINK: https://app.webinar.net/a9kpB2jB7nW
TRADITIONAL DIAL-IN NUMBER: 1-888-664-6392 or 416-764-8659
RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/3ZK16TS
TAPED REPLAY: 1-888-390-0541 or 416-764-8677
REPLAY CODE: 864357#
The taped replay will be available for 14 days and the archived webcast will be available for 365 days.
A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.
Copyright 2023 Canada NewsWire
1 Year HLS Therapeutics Chart |
1 Month HLS Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
